Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sheng Yong

Showing results (401-410 of 421) with videos related to

Pageof 43
Sort By:
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|June 22, 2011
SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivoZhi-Xing Cao, Ren-Lin Zheng, Hong-Jun Lin, et al.
Journal of Medical Internet Research|August 6, 2025
Classifying Patient Complaints Using Artificial Intelligence-Powered Large Language Models: Cross-Sectional StudySky Wei Chee Koh, Eunice Rui Ning Wong, John Chong Min Tan, et al.
ACS Chemical Biology|February 28, 2024
Functional and Promiscuity Studies of Three-Residue Cyclophane Forming Enzymes Show Nonnative C-C Cross-Linked Products and Leader-Dependent CyclizationAngelica Faith L Suarez, Thi Quynh Ngoc Nguyen, Litao Chang, et al.
Molecular Cancer Therapeutics|February 10, 2012
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivoYouli Pan, Yong Xu, Shan Feng, et al.
Cell Death & Disease|September 28, 2019
Correction: Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasisTing-Hong Ye, Fang-Fang Yang, Yong-Xia Zhu, et al.
Cell Death & Disease|January 6, 2017
Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasisTing-Hong Ye, Fang-Fang Yang, Yong-Xia Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2022
Inferring gene regulation from stochastic transcriptional variation across single cells at steady stateAnika Gupta, Jorge D Martin-Rufino, Thouis R Jones, et al.
European Journal of Medicinal Chemistry|November 15, 2017
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutantsJiao Yang, Kai Chen, Guo Zhang, et al.
Journal of Medicinal Chemistry|October 15, 2016
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast CancerChun-Hui Zhang, Kai Chen, Yan Jiao, et al.
Journal of Medicinal Chemistry|April 4, 2015
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast CancerChun-Hui Zhang, Ming-Wu Zheng, Ya-Ping Li, et al.
Pageof 43

Showing results (401-410 of 421) with videos related to

Sort By:
Pageof 43
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|June 22, 2011
SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivoZhi-Xing Cao, Ren-Lin Zheng, Hong-Jun Lin, et al.
Journal of Medical Internet Research|August 6, 2025
Classifying Patient Complaints Using Artificial Intelligence-Powered Large Language Models: Cross-Sectional StudySky Wei Chee Koh, Eunice Rui Ning Wong, John Chong Min Tan, et al.
ACS Chemical Biology|February 28, 2024
Functional and Promiscuity Studies of Three-Residue Cyclophane Forming Enzymes Show Nonnative C-C Cross-Linked Products and Leader-Dependent CyclizationAngelica Faith L Suarez, Thi Quynh Ngoc Nguyen, Litao Chang, et al.
Molecular Cancer Therapeutics|February 10, 2012
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivoYouli Pan, Yong Xu, Shan Feng, et al.
Cell Death & Disease|September 28, 2019
Correction: Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasisTing-Hong Ye, Fang-Fang Yang, Yong-Xia Zhu, et al.
Cell Death & Disease|January 6, 2017
Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasisTing-Hong Ye, Fang-Fang Yang, Yong-Xia Zhu, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 15, 2022
Inferring gene regulation from stochastic transcriptional variation across single cells at steady stateAnika Gupta, Jorge D Martin-Rufino, Thouis R Jones, et al.
European Journal of Medicinal Chemistry|November 15, 2017
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutantsJiao Yang, Kai Chen, Guo Zhang, et al.
Journal of Medicinal Chemistry|October 15, 2016
From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast CancerChun-Hui Zhang, Kai Chen, Yan Jiao, et al.
Journal of Medicinal Chemistry|April 4, 2015
Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast CancerChun-Hui Zhang, Ming-Wu Zheng, Ya-Ping Li, et al.
Pageof 43